EPCAM and neoplasm: Despite the higher percentages of CD133+/EpCAM+ cells in the cultured CSC population, the percentage of CD133+/EpCAM+ cells in the xenograft tumors declined to 4–6%, which is consistent with the percentage of CD133+/EpCAM+ cells observed in the original patient tumor (Fig. 1Bc and Fig. 4A).